Switch theme
Sign up to access all valuation multiples
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world’s prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
2016
1.8K+
LTM Revenue $291M
LTM EBITDA -$37.1M
$8.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kelun-Biotech has a last 12-month revenue (LTM) of $291M and a last 12-month EBITDA of -$37.1M.
In the most recent fiscal year, Kelun-Biotech achieved revenue of $247M and an EBITDA of -$6.0M.
Kelun-Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kelun-Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $291M | XXX | $247M | XXX | XXX | XXX |
| Gross Profit | $200M | XXX | $163M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | -$37.1M | XXX | -$6.0M | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | -2% | XXX | XXX | XXX |
| EBIT | -$50.2M | XXX | -$27.0M | XXX | XXX | XXX |
| EBIT Margin | -17% | XXX | -11% | XXX | XXX | XXX |
| Net Profit | -$61.2M | XXX | -$34.0M | XXX | XXX | XXX |
| Net Margin | -21% | XXX | -14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kelun-Biotech's stock price is HKD 319 (or $41).
Kelun-Biotech has current market cap of HKD 72.5B (or $9.3B), and EV of HKD 69.3B (or $8.8B).
See Kelun-Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.8B | $9.3B | XXX | XXX | XXX | XXX | $-0.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kelun-Biotech has market cap of $9.3B and EV of $8.8B.
Kelun-Biotech's trades at 35.9x EV/Revenue multiple, and -1464.0x EV/EBITDA.
Equity research analysts estimate Kelun-Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kelun-Biotech has a P/E ratio of -164.4x.
See valuation multiples for Kelun-Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.3B | XXX | $9.3B | XXX | XXX | XXX |
| EV (current) | $8.8B | XXX | $8.8B | XXX | XXX | XXX |
| EV/Revenue | 33.1x | XXX | 35.9x | XXX | XXX | XXX |
| EV/EBITDA | -259.1x | XXX | -1464.0x | XXX | XXX | XXX |
| EV/EBIT | -191.6x | XXX | -328.0x | XXX | XXX | XXX |
| EV/Gross Profit | 48.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -164.4x | XXX | -271.9x | XXX | XXX | XXX |
| EV/FCF | -169.9x | XXX | -135.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKelun-Biotech's last 12 month revenue growth is 26%
Kelun-Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Kelun-Biotech's rule of 40 is 6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kelun-Biotech's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kelun-Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | -2% | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 6% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 77% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kelun-Biotech acquired XXX companies to date.
Last acquisition by Kelun-Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Kelun-Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kelun-Biotech founded? | Kelun-Biotech was founded in 2016. |
| Where is Kelun-Biotech headquartered? | Kelun-Biotech is headquartered in Hong Kong. |
| How many employees does Kelun-Biotech have? | As of today, Kelun-Biotech has 1.8K+ employees. |
| Is Kelun-Biotech publicy listed? | Yes, Kelun-Biotech is a public company listed on HKG. |
| What is the stock symbol of Kelun-Biotech? | Kelun-Biotech trades under 06990 ticker. |
| When did Kelun-Biotech go public? | Kelun-Biotech went public in 2023. |
| Who are competitors of Kelun-Biotech? | Similar companies to Kelun-Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Kelun-Biotech? | Kelun-Biotech's current market cap is $9.3B |
| What is the current revenue of Kelun-Biotech? | Kelun-Biotech's last 12 months revenue is $291M. |
| What is the current revenue growth of Kelun-Biotech? | Kelun-Biotech revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of Kelun-Biotech? | Current revenue multiple of Kelun-Biotech is 33.1x. |
| Is Kelun-Biotech profitable? | Yes, Kelun-Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kelun-Biotech? | Kelun-Biotech's last 12 months EBITDA is -$37.1M. |
| What is Kelun-Biotech's EBITDA margin? | Kelun-Biotech's last 12 months EBITDA margin is -13%. |
| What is the current EV/EBITDA multiple of Kelun-Biotech? | Current EBITDA multiple of Kelun-Biotech is -259.1x. |
| What is the current FCF of Kelun-Biotech? | Kelun-Biotech's last 12 months FCF is -$56.6M. |
| What is Kelun-Biotech's FCF margin? | Kelun-Biotech's last 12 months FCF margin is -19%. |
| What is the current EV/FCF multiple of Kelun-Biotech? | Current FCF multiple of Kelun-Biotech is -169.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
